Non-Regulatory

May 19, 2017

Interim Report – January to March 2017

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued...

Read more

Non-Regulatory

May 10, 2017

Affibody To Initiate Phase II Psoriasis Trials For Lead Candidate ABY-035

Solna, Sweden, May 10, 2017. Affibody AB (“Affibody”) today announced that it has decided to initiate Phase II development with ABY-035, which is the company’s proprietary psoriasis program.

Read more

Non-Regulatory

February 24, 2017

Year End Report 2016

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more

Non-Regulatory

November 18, 2016

Interim Report – January to September 2016

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more

Non-Regulatory

October 13, 2016

Affibody’s Collaborator Dartmouth Wins FDA Approval for Aid to Guide Cancer Surgery

In a major milestone for Dartmouth and for the future of molecularly guided cancer surgery, Dartmouth has gained FDA approval for a study that may give surgeons a new...

Read more

Non-Regulatory

August 19, 2016

Interim Report – January to June 2016

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more

Non-Regulatory

May 20, 2016

Interim Report – January to March 2016

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more

Non-Regulatory

May 4, 2016

Affibody Announces Initial Results from a Phase I Study of ABY-035

Solna, Sweden, May 4, 2016. Affibody AB (“Affibody”) today announced that it has completed the dose-escalation part of a Phase I study of ABY-035, which is the company’s proprietary...

Read more

Non-Regulatory

April 22, 2016

Sobi™ Signs Licensing Agreement with Affibody for IL-1

Solna, Sweden, April 22, 2016 – Swedish Orphan Biovitrum AB (publ) (Sobi™) today announced that it has exercised its option to sign a licensing agreement with Swedish biotech company...

Read more